GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Processa Pharmaceuticals Inc (NAS:PCSA) » Definitions » Degree of Operating Leverage

PCSA (Processa Pharmaceuticals) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Processa Pharmaceuticals Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Processa Pharmaceuticals does not have enough data to calculate Degree of Operating Leverage.


Processa Pharmaceuticals Degree of Operating Leverage Historical Data

The historical data trend for Processa Pharmaceuticals's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Processa Pharmaceuticals Degree of Operating Leverage Chart

Processa Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Processa Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Processa Pharmaceuticals's Degree of Operating Leverage

For the Biotechnology subindustry, Processa Pharmaceuticals's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Processa Pharmaceuticals's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's Degree of Operating Leverage falls into.


;
;

Processa Pharmaceuticals Degree of Operating Leverage Calculation

Processa Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -12.089 (Mar. 2025) / -10.161 (Mar. 2024) - 1 )/( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 )
=0.1897/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Processa Pharmaceuticals  (NAS:PCSA) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Processa Pharmaceuticals Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Processa Pharmaceuticals's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Processa Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
7380 Coca Cola Drive, Suite 106, Hanover, MD, USA, 21076
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Executives
George K Ng officer: Chief Executive Officer C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121
Justin W Yorke director C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101
David Young director, 10 percent owner, officer: President & CEO 8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045
Patrick Lin officer: Chief Business - Strategy Off 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Wendy Guy officer: Chief Administrative Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James H Stanker officer: Chief Financial Officer 9008 SHADYBROOK DRIVE, FREDERICK MD 21701
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Virgil Thompson director 319 SOUTH NARDO, SOIANA BEACH CA 92075
Geraldine Pannu director 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Robert Michael Floyd officer: Chief Operating Officer C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sian Bigora officer: Chief Development Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076